Revised dosing of Ciprofloxacin for patients with impaired renal function: a bioequivalence study

To assess bioequivalence of ciprofloxacin between patients with impaired renal function (eGFR < 30 ml/min/1.73m2) receiving the revised reduced doses (test, 750 mg orally once daily or 600 mg intravenously once daily) and patients with adequate renal function receiving regular doses (reference, 500mg orally twice daily or 400 mg intravenously twice daily), by investigating whether drug exposure in the first 24 hours of treatment (AUC024) is bioequivalent between both patient groups (test/reference).